Dinko Rekić

753 total citations
29 papers, 451 citations indexed

About

Dinko Rekić is a scholar working on Surgery, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Dinko Rekić has authored 29 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 6 papers in Infectious Diseases and 6 papers in Molecular Biology. Recurrent topics in Dinko Rekić's work include Lipoproteins and Cardiovascular Health (6 papers), HIV/AIDS drug development and treatment (6 papers) and HIV Research and Treatment (5 papers). Dinko Rekić is often cited by papers focused on Lipoproteins and Cardiovascular Health (6 papers), HIV/AIDS drug development and treatment (6 papers) and HIV Research and Treatment (5 papers). Dinko Rekić collaborates with scholars based in Sweden, United States and United Kingdom. Dinko Rekić's co-authors include Yaning Wang, Banu A. Karimi-Shah, Youwei Bi, Badrul A. Chowdhury, Daniel Röshammar, Michael Ashton, Kellie S. Reynolds, Kenta Yoshida, Ping Zhao and Lei Zhang and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and PLoS ONE.

In The Last Decade

Dinko Rekić

28 papers receiving 445 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dinko Rekić Sweden 11 143 78 69 66 63 29 451
Birgitta Grundmark Sweden 13 98 0.7× 95 1.2× 36 0.5× 50 0.8× 30 0.5× 18 593
Kathrin I. Foerster Germany 13 98 0.7× 55 0.7× 83 1.2× 66 1.0× 105 1.7× 39 651
Huaijun Zhu China 16 95 0.7× 99 1.3× 113 1.6× 49 0.7× 52 0.8× 60 772
Zhiying Luo China 16 64 0.4× 149 1.9× 86 1.2× 51 0.8× 70 1.1× 40 717
Elena Guerini Switzerland 15 222 1.6× 208 2.7× 81 1.2× 48 0.7× 24 0.4× 29 793
Ulrika Wählby Sweden 7 42 0.3× 100 1.3× 61 0.9× 55 0.8× 29 0.5× 8 598
Chengxian Guo China 18 108 0.8× 171 2.2× 132 1.9× 85 1.3× 21 0.3× 76 804
Yusong Chen China 11 221 1.5× 136 1.7× 74 1.1× 30 0.5× 61 1.0× 23 884
Yoshiaki Ohtsu Japan 10 184 1.3× 87 1.1× 72 1.0× 22 0.3× 35 0.6× 26 477
Tsugumichi Sato Japan 13 38 0.3× 73 0.9× 36 0.5× 34 0.5× 84 1.3× 41 753

Countries citing papers authored by Dinko Rekić

Since Specialization
Citations

This map shows the geographic impact of Dinko Rekić's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dinko Rekić with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dinko Rekić more than expected).

Fields of papers citing papers by Dinko Rekić

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dinko Rekić. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dinko Rekić. The network helps show where Dinko Rekić may publish in the future.

Co-authorship network of co-authors of Dinko Rekić

This figure shows the co-authorship network connecting the top 25 collaborators of Dinko Rekić. A scholar is included among the top collaborators of Dinko Rekić based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dinko Rekić. Dinko Rekić is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rekić, Dinko, Angelica Quartino, Björn Carlsson, et al.. (2024). Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide. British Journal of Clinical Pharmacology. 90(6). 1503–1513. 1 indexed citations
2.
Parkinson, Joanna, Dinko Rekić, Karin Nelander, et al.. (2024). The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses. Pharmacology Research & Perspectives. 12(2). e1184–e1184. 2 indexed citations
3.
4.
Koren, Michael J., Alexis Hofherr, Jennifer Schumi, et al.. (2022). ETESIAN: A PHASE 2B STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF AZD8233, A PCSK9-TARGETED ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH DYSLIPIDEMIA. Journal of the American College of Cardiology. 79(9). 1475–1475. 14 indexed citations
5.
Aoki, Yasunori, Claudia Cabrera, Mario Ouwens, et al.. (2022). Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data. PLoS ONE. 17(6). e0269970–e0269970. 4 indexed citations
6.
Parkinson, Joanna, Corina Dota, Magnus Bjursell, et al.. (2022). Verinurad does not prolong QTc interval: a thorough QT study using concentration–QTc modelling. British Journal of Clinical Pharmacology. 89(6). 1747–1755. 2 indexed citations
7.
Voronova, Veronika, Marie Cullberg, Joanna Parkinson, et al.. (2021). Concentration‐QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations. British Journal of Clinical Pharmacology. 88(2). 858–864. 6 indexed citations
8.
Rekić, Dinko, Mats Någård, James Chou, et al.. (2021). Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. Clinical Pharmacokinetics. 60(6). 759–773. 12 indexed citations
9.
Berges, Aliénor, et al.. (2021). QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small‐Molecule New Drug Applications Approved During 2011‐2019. The Journal of Clinical Pharmacology. 61(8). 1106–1117. 12 indexed citations
10.
Rekić, Dinko, et al.. (2020). Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight. Clinical Pharmacokinetics. 60(3). 319–328. 3 indexed citations
11.
Bi, Youwei, Dinko Rekić, Jianmeng Chen, et al.. (2020). A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients. Journal of Pharmacokinetics and Pharmacodynamics. 48(1). 55–67. 5 indexed citations
12.
Bi, Youwei, et al.. (2017). Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society. 14(9). 1395–1402. 124 indexed citations
13.
Rekić, Dinko, Kellie S. Reynolds, Ping Zhao, et al.. (2017). Clinical Drug–Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access. Journal of Pharmaceutical Sciences. 106(9). 2214–2218. 47 indexed citations
14.
Yoshida, Kenta, Ping Zhao, Lei Zhang, et al.. (2017). In Vitro–In Vivo Extrapolation of Metabolism- and Transporter-Mediated Drug–Drug Interactions—Overview of Basic Prediction Methods. Journal of Pharmaceutical Sciences. 106(9). 2209–2213. 61 indexed citations
15.
Rekić, Dinko, Daniel Röshammar, & Ulrika S. H. Simonsson. (2013). Model based design and analysis of phase II HIV-1 trials. Journal of Pharmacokinetics and Pharmacodynamics. 40(4). 487–496. 6 indexed citations
16.
Rekić, Dinko, Daniel Röshammar, Martin Bergstrand, et al.. (2012). External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients. The AAPS Journal. 15(2). 308–315. 3 indexed citations
17.
Mukonzo, Jackson, Dinko Rekić, Paul Waako, et al.. (2011). HIV/AIDS Patients Display Lower Relative Bioavailability of Efavirenz than Healthy Subjects. Clinical Pharmacokinetics. 50(8). 531–540. 25 indexed citations
18.
Rekić, Dinko, Daniel Röshammar, Leo Flamholc, et al.. (2011). Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy. The AAPS Journal. 13(4). 598–605. 11 indexed citations
19.
Barregård, Lars, et al.. (2011). Toxicokinetics of Mercury after Long-Term Repeated Exposure to Thimerosal-Containing Vaccine. Toxicological Sciences. 120(2). 499–506. 32 indexed citations
20.
Rekić, Dinko, Daniel Röshammar, Jackson Mukonzo, & Michael Ashton. (2010). In silicoprediction of efavirenz and rifampicin drug–drug interaction considering weight and CYP2B6 phenotype. British Journal of Clinical Pharmacology. 71(4). 536–543. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Birgitta Grundmark Breakdown of academic impact, for papers by Kathrin I. Foerster Breakdown of academic impact, for papers by Huaijun Zhu Breakdown of academic impact, for papers by Zhiying Luo Breakdown of academic impact, for papers by Elena Guerini Breakdown of academic impact, for papers by Ulrika Wählby Breakdown of academic impact, for papers by Chengxian Guo Breakdown of academic impact, for papers by Yusong Chen Breakdown of academic impact, for papers by Yoshiaki Ohtsu Breakdown of academic impact, for papers by Tsugumichi Sato
Rankless by CCL
2026